Search
Assertio Holdings Inc
ASRTAdd to Watchlist
23.495USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
151.86MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
-0.02%
1 Month
+0.19%
6 Months
+157.06%
Year to Date
+159.04%
1 Year
+3498.01%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
377.21P/E Dynamic
--Dividend TTM
4.26%Turnover Ratio
23.500Prev. Close
0.000Low
0.00Turnover
LossP/E Static
1.61P/B
0.00%Div Yield TTM
-14.34%ROA
23.46052wk High
0.58Volume Ratio
-21.58MNet Profit
6.42MShares
-5.5516EPS TTM
0.50Beta
-38.76%ROE
8.61052wk Low
0.09%Amplitude
14.28%Gross Margin
151.86MMarket Cap
0.22Reward/Risk
3.17%Risk Rate
TradingKey Stock Score of Assertio Holdings Inc
Currency: USD Updated: 2026-06-15Key Insights
Assertio Holdings Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 96 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 24.43.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Assertio Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Assertio Holdings Inc Highlights
StrengthsRisks
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Undervalued
The company’s latest PE is -4.23, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.20M shares, decreasing 3.11% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
24.433
Target Price
+3.97%
Upside Space
Assertio Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Assertio Holdings Inc Info
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Ticker SymbolASRT
CompanyAssertio Holdings Inc
CEOReisenauer (Mark L)
Websitehttps://www.assertiotx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Assertio Holdings Inc (ASRT)?
The current price of Assertio Holdings Inc (ASRT) is 23.50.
What is the symbol of Assertio Holdings Inc?
The ticker symbol of Assertio Holdings Inc is ASRT.
What is the 52-week high of Assertio Holdings Inc?
The 52-week high of Assertio Holdings Inc is 23.46.
What is the 52-week low of Assertio Holdings Inc?
The 52-week low of Assertio Holdings Inc is 8.61.
What is the market capitalization of Assertio Holdings Inc?
The market capitalization of Assertio Holdings Inc is 151.86M.
What is the Earnings Per Share (EPS TTM) of Assertio Holdings Inc (ASRT)?
The Earnings Per Share (EPS TTM) of Assertio Holdings Inc (ASRT) is -4.74.